Clinical Trials Browser

Granulosa cell tumor of the ovary

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

Breast Neoplasms, Breast Neoplasms, Male

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Hormone Sensitive Prostate Cancer

Prostatic Neoplasms

Stage I Prostate Adenocarcinoma AJCC v7

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Salivary Gland Neoplasms

Salivary Gland Neoplasm Duct

Prostatic Neoplasms

HER2-positive Breast Cancer

Prostatic Neoplasms

Salivary Gland Neoplasms

Carcinoma, Non-Small-Cell Lung

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Newly Diagnosed Oligometastatic Prostate Cancer

Prostatic Neoplasms

Clinical Trials

Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

CARABELA

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Rezvilutamide for High-Risk Prostate Cancer After Surgery

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

ARCH

Adjuvant WIDER

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

REVELUTION

COAction

e3

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

CASPAR

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

AASUR in High Risk Prostate Cancer

NePtune

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

BYLieve

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

STEEL

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

DIVINE

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

POP-ELA

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

ADEPT

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

The COSMYC Trial (COmbined Suppression of MYC)

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

CARLHA-2